Nucleocapsid antibody positivity as a marker of past SARS-CoV-2 infection in population serosurveillance studies: impact of variant, vaccination, and choice of assay cut-off [article]

Heather J Whitaker, Charlotte Gower, Ashley D Otter, Ruth Simmons, Freja Kirsebom, Louise Letley, Catherine Quinot, Georgina Ireland, Ezra Linley, Sonia Ribeiro, Shamez Ladhani, Jamie Lopez-Bernal (+3 others)
2021 medRxiv   pre-print
Serological surveillance studies sometimes use presence of anti-nucleocapsid antibody as a marker of natural SARS-CoV-2 infection. We explore seroconversion rates and antibody titres following Alpha and Delta variant infections, and vaccine breakthrough infections. We find lower seroconversion rates particularly following Alpha-variant vaccine breakthrough infections. We re-evaluate assay performance with a mix of past waned infections and recent breakthrough infections, that is relevant to current serological surveillance.
doi:10.1101/2021.10.25.21264964 fatcat:rw3st3tlrbhivbozxbzbzvwlyq